...working with Altasciences has been excellent, from both a bioanalytical, and a bioavailability study perspective. We are really impressed with their planning and execution abilities – I would not consider another provider for future work.
Read the blog
In Phase I ethnobridging clinical trials, there are three primary protocol design concepts utilized. These concepts align the strategy with global clinical development and measure key factors necessary for meeting the unique needs of the Sponsor.
Altasciences is expanding its current clinical operations in Montreal and Kansas City with the addition of a clinical CRO on the U.S.A.'s West Coast. Click below to read more about the acquisition of WCCT Global.
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
From formulation development, Phase I through commercial manufacturing, and ICH stability testing
As part of our full service offering or as standalone solutions
Comprehensive CRO services to support clinical and preclinical studies
Passive immunotherapy refers to the transfer of antibodies to an unprotected individual for the treatment or prevention of disease. Monoclonal antibodies (mAbs) offer several advantages as passive immunotherapeutic agents since they can be manufactured at large scale with inherently high specificity and consistency.
In this complimentary presentation, we summarize how we developed a hybrid LC-MRM workflow for the quantitation of mAbs used as passive immunotherapeutic agents of viral infections. The workflow is generic and does not rely on highly specific critical reagents. More importantly, it offers the potential for multiplexing should a combination of different antiviral mAbs be dosed simultaneously.
Join our list of 10,000+ VIP members and have access to our exclusive content.